Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
AstraZeneca
Merck
Harvard Business School
Mallinckrodt

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR TIOTROPIUM BROMIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Tiotropium Bromide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00139932 ↗ Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272) Completed Integrated Therapeutics Group Phase 4 2005-09-01 This study is being conducted to determine if the co-administration of formoterol fumarate and tiotropium bromide is more effective than the use of tiotropium bromide alone in patients with COPD.
NCT00139932 ↗ Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272) Completed Novartis Phase 4 2005-09-01 This study is being conducted to determine if the co-administration of formoterol fumarate and tiotropium bromide is more effective than the use of tiotropium bromide alone in patients with COPD.
NCT00139932 ↗ Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272) Completed Merck Sharp & Dohme Corp. Phase 4 2005-09-01 This study is being conducted to determine if the co-administration of formoterol fumarate and tiotropium bromide is more effective than the use of tiotropium bromide alone in patients with COPD.
NCT00144326 ↗ A Randomised, Double-blind, Placebo-controlled, 12 Week Trial to Evaluate the Effect of Tiotropium Inhalation Capsules (Spiriva) on the Magnitude of Exercise, Measured Using an Accelerometer, in Patients With Chronic Obstructive Pulmonary Disease (C Completed Boehringer Ingelheim Phase 3 2003-07-01 The objective of this study is to determine if tiotropium (Spiriva, Bromuro de Tiotropio) 18 mcg once daily by oral inhalation compared to placebo increases the magnitude of daily physical activity observed in COPD patients, measured using an accelerometer.
NCT00157235 ↗ Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients Completed Boehringer Ingelheim Phase 3 2002-09-01 The objective of this trial is to determine whether tiotropium inhalation capsules (Spiriva, Bromuro de Tiotropio), compared to placebo, enhances the improvement in exercise tolerance seen in patients with chronic obstructive pulmonary disease (COPD) who participate in pulmonary rehabilitation.
NCT00239408 ↗ Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal). Completed Boehringer Ingelheim Phase 4 2002-12-01 Evaluate whether the effect of inhaled tiotropium bromide on the change in trough forced expiratory volume (FEV1), compared to placebo in patients with chronic obstructive pulmonary disease (COPD), is affected by smoking status.
NCT00239434 ↗ A Comparison of 18g of Tiotropium Inhalation Capsules Once Daily and Atrovent Metered Dose Inhaler (2 Puffs of 20g, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD) Completed Boehringer Ingelheim Phase 3 2003-06-01 The objective of this study is to compare the bronchodilator efficacy and safety of once daily dosing of tiotropium inhalation capsules (18 ?g) and Atrovent? MDI (2 puffs of ipratropium bromide 20 ?g four times daily) in patients with chronic obstructive pulmonary disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tiotropium Bromide

Condition Name

Condition Name for Tiotropium Bromide
Intervention Trials
Pulmonary Disease, Chronic Obstructive 50
Chronic Obstructive Pulmonary Disease 23
COPD 11
Asthma 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tiotropium Bromide
Intervention Trials
Pulmonary Disease, Chronic Obstructive 83
Lung Diseases 78
Chronic Disease 49
Lung Diseases, Obstructive 48
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tiotropium Bromide

Trials by Country

Trials by Country for Tiotropium Bromide
Location Trials
United States 456
Germany 65
Canada 64
Italy 35
Japan 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tiotropium Bromide
Location Trials
South Carolina 26
California 26
Florida 25
Texas 24
Ohio 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tiotropium Bromide

Clinical Trial Phase

Clinical Trial Phase for Tiotropium Bromide
Clinical Trial Phase Trials
Phase 4 33
Phase 3 33
Phase 2 23
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tiotropium Bromide
Clinical Trial Phase Trials
Completed 99
Unknown status 6
Not yet recruiting 3
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tiotropium Bromide

Sponsor Name

Sponsor Name for Tiotropium Bromide
Sponsor Trials
Boehringer Ingelheim 48
GlaxoSmithKline 15
Novartis 6
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tiotropium Bromide
Sponsor Trials
Industry 102
Other 54
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Harvard Business School
Boehringer Ingelheim
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.